West Nile virus and the central nervous system by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
BMC Proceedings
Open AccessOral presentation
West Nile virus and the central nervous system
Kenneth L Tyler
Address: Departments of Neurology, Medicine, and Microbiology University of Colorado at Denver Health Sciences Center, Denver, CO 80262 
USA, and Neurology Service Denver VA Medical Center, Denver, CO 80220 USA
Email: Kenneth L Tyler - ken.tyler@uchsc.edu
Following its emergence in the Western Hemisphere in
1999, West Nile virus (WNV) has become endemic and is
now the most important cause of arboviral meningoen-
cephalitis in the United States. Approximately 1% of
infected individuals develop neuroinvasive disease which
can take the form of encephalitis, meningitis, or acute flac-
cid paralysis (poliomyelitis-like illness). The current epi-
demiology and clinical features of the different forms of
WNV neuroinvasive disease will be discussed. In distinc-
tion to many other forms of viral meningoencephalitis,
WNV disease is frequently associated with a CSF neu-
trophil rather than lymphocyte predominant CSF pleocy-
tosis. The CSF characteristics of WNV disease will be
reviewed. Neuroimaging is less frequently abnormal in
WNV encephalitis than in some other types of acute
encephalitis (e.g. herpes simplex encephalitis). The basic
neuroimaging features of WNV encephalitis will be
reviewed including the predilection for abnormalities
involving the basal ganglia, thalamus and upper brain-
stem. Although seizures are unusual in WNV encephalitis,
it has been suggested that anteriorly predominant slowing
on EEG may be a clue to the diagnosis. EMG/NCV abnor-
malities are characteristic of WNV AFP and can include
absence or decrease in Compound Motor Action Poten-
tials (CMAPs) with preserved Sensory Nerve Action Poten-
tials (SNAPs) as well as the presence of EMG signs of
denervation. Serology remains the mainstay of diagnosis,
with detection of WNV specific IgM in CSF being generally
diagnostic of WNV neurological disease. The kinetics and
application of serology and other diagnostic tests includ-
ing CSF PCR will be discussed. There is currently no
known specific therapy for WNV infection, however a
variety of clinical trials involving interferon-alpha, intra-
venous immunoglobulin (IVIG) with high titer WNV anti-
body (e.g. Omr-IgG-am), and humanized monoclonal
antibody against WNV envelope protein domains have
been initiated and will be reviewed. Several WNV vaccines
have now been licensed for veterinary use and the current
status of human vaccine development and trials will be
reviewed. Although there is currently no evidence that
WNV produces chronic, persistent or recurrent disease in
immunocompetent humans, some studies of WNV infec-
tion have suggested that a significant number of individu-
als may have long-term sequelae following acute infection
including possible cognitive impairment, alterations in
mood, fatigue, weakness and pain.
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